- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07258576
Cycle menstruel vs. contraceptifs oraux : effets sur le métabolisme des protéines musculaires après un exercice de résistance (MCOC)
L'effet de la phase du cycle menstruel et de l'utilisation de contraceptifs oraux sur le métabolisme des protéines musculaires après un entraînement en résistance
The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle.
Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons.
Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body.
The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 2C9
- Goldring Center for High Performance Sport
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age: 18-40 years
- BMI between 18.5-29.9 kg/m2 (non-obese)
- Recreationally active (resistance train minimum twice a week)
- Using monophasic or triphasic oral contraceptives for >1 year (for oral contraceptive users)
- Have regular menstrual cycles (21-35 days) for the past 3 months and discontinued any hormonal contraceptive use for at least 6 months (non-oral contraceptive users)
- Must meet a progesterone sufficiency test (non-oral contraceptive users)
Exclusion Criteria:
- Mid-luteal progesterone levels <16umol
- Chronic disease diagnosis (cardiovascular, thyroid, diabetes)
- Current or recent remission of cancer
- Regular use of non-steroidal anti-inflammatory drugs (NSAIDs; except low-dose aspirin), anticoagulants
- Use of prescription drugs that would impact muscle protein synthesis, e.g. Statins, Lithium, ADHD medication.
- Insertion of intrauterine device (IUD) - exception: copper
- Use of emergency contraception in the last 3 months (e.g. Plan B)
- Severe food allergies (e.g. soy, nuts)
- Smoking, use of performance enhancing drugs (growth hormones, testosterone)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Mid-Luteal Phase
5-9 days post-ovulation |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
|
Autre: Early Follicular Phase
Days 2-6 post-menses onset |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
|
Autre: Active Pill Phase
Days 10-20 of active pill |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
|
Autre: Placebo Pill Phase
At least 48h after last active pill is taken |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Muscle Protein Synthesis (MPS)
Délai: 8 hours
|
Muscle protein synthesis (MPS) will be assessed during an 8-hour post-exercise and feeding period using a stable isotope tracer, L-[ring-D5]phenylalanine ([D5]Phe). The incorporation of the [D5]Phe tracer into myofibrillar muscle proteins, collected from muscle biopsies (pre-exercise and post-8h feeding), will be analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to determine the fractional synthesis rate (FSR) of muscle proteins. This will help us understand how menstrual cycle phases and oral contraceptive use influence MPS, providing insight into optimizing protein intake and training adaptations in female athletes. |
8 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Whole Body Protein Synthesis (WBPS)
Délai: 4 hours
|
Whole body protein synthesis (WBPS) will be measured over a 4-hour period using the Indicator Amino Acid Oxidation (IAAO) methodology. Participants will consume a stable isotope tracer, L-[1-13C]phenylalanine ([13C]Phe), and breath samples will be collected every 30 minutes during the final 4 hours of the metabolic trial. The enrichment of 13CO₂ in breath samples will be analyzed to determine phenylalanine oxidation rates, providing an estimate of whole-body protein turnover and dietary protein utilization. This will allow us to assess whether hormonal fluctuations influence protein metabolism and nutritional requirements in female athletes. |
4 hours
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- MCOC - REB00048059
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .